The AnteAGE® Team

A skincare product is only a good as the team behind it. AnteAGE® is led by renowned researchers, scientists and physicians who are the best in their field. Our team is regularly published in scientific journals, awarded for groundbreaking results, and sought for expertise by Fortune 100 healthcare companies.


Our Science and Executive Team


John Sanderson M.D.

John Sanderson M.D.

CEO/Founder

Dr. Sanderson is a stem cell researcher who began his career in clinical medicine specializing in diabetes and intravenous nutrition of critically ill patients. He has received NIH funding, has multiple issued patents and published numerous academic papers as principal investigator. While a medical director and consultant at Johnson & Johnson, Dr. Sanderson was tasked with due diligence oversight for mergers and acquisition, formulating strategic initiatives, and evaluating new technologies.

As a consultant to Fortune 100 health care companies and the U.S. government, Dr. Sanderson worked with some of the greatest minds of the day devising technological solutions to important public health challenges such as obesity, diabetes, and asthma.  In recent years, Dr. Sanderson has focused exclusively on the application of adult stem cells to dermatologic problems and effects of ageing.


George E. Taylor, MD

George E. Taylor, MD

President/Medical Director

George E. Taylor, MD has participated in a number of diabetes related projects including clinical and laboratory research, and article and grant authorship. It was his work relating to diabetes, wound healing, and cell culture that lead to his collaboration with Dr. Sanderson in the development and clinical testing of AnteAGE. Dr. Taylor has served as a venture capital liaison, and executive for several pharmaceutical start-ups. He began his career as a pediatric and adult anesthesiologist and retired from clinical medicine in 2000 following a sports injury. His diverse experience includes serving as medical director for a home health and hospice agency, over-seeing the medical testing and regulatory approval of a new class of plastics additive which included national and international marketing duties.